Partners Karen Lent and Kenneth Schwartz review some of the most notable antitrust activity in the health care and pharmaceutical industries over the past year and discuss how these developments hint at a more aggressive approach to enforcement by the DOJ and FTC in 2024.
Upping the Dosage: Health Care and Pharmaceuticals Antitrust Regulation in 2023
New York Law Journal